Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort
Portfolio Pulse from
Oncolytics Biotech has completed the initial safety phase enrollment for the GOBLET trial's new pancreatic cancer cohort. The Data Safety Monitoring Board has recommended continued enrollment based on early safety results. The trial involves pelareorep combined with modified FOLFIRINOX, with or without atezolizumab.
December 03, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncolytics Biotech has received a positive recommendation from the DSMB to continue enrollment in the GOBLET trial's pancreatic cancer cohort after initial safety results. This could lead to further advancements in their clinical trials.
The DSMB's recommendation to continue enrollment in the GOBLET trial indicates positive initial safety results, which is a crucial step in clinical trials. This development is likely to boost investor confidence and could positively impact ONCY's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90